Blood Microbiota Modification After Myocardial Infarction Depends Upon Low-Density Lipoprotein Cholesterol Levels

Jacques Amar, Benjamin Lelouvier, Florence Servant, Jérôme Lluch, Rémy Burcelin, Vanina Bongard, Meyer Elbaz, Jacques Amar, Benjamin Lelouvier, Florence Servant, Jérôme Lluch, Rémy Burcelin, Vanina Bongard, Meyer Elbaz

Abstract

Background The role of bacteria on the onset of cardiovascular disease has been suggested. Reciprocally, increased intestinal bacterial translocation and bloodstream infection are common comorbidities associated with heart failure and myocardial infarction (MI). In this context, the aim of this study was to analyze the blood microbiome in patients shortly after acute myocardial infarction. Methods and Results We carried out a case control study comparing 103 patients at high cardiovascular risk but free of coronary disease and 99 patients who had an MI. The blood microbiome was analyzed both quantitatively by 16S quantitative polymerase chain reaction and qualitatively by 16S targeted metagenomic sequencing specifically optimized for blood samples. A significant increase in blood bacterial 16S rDNA concentration was observed in patients admitted for MI. This increase in blood bacterial DNA concentration was independent of post-MI left ventricular function and was more marked in patients with low-density lipoprotein cholesterol ≥1 g/L. In addition, differences in the proportion of numerous bacterial taxa in blood were significantly modified with the onset of MI, thus defining a blood microbiota signature of MI. Among the bacterial taxa whose proportions are decreased in patients with MI, at least 6 are known to include species able to metabolize cholesterol. Conclusions These results could provide the basis for the identification of blood microbiome-based biomarkers for the stratification of MI patients. Furthermore, these findings should provide insight into the mechanism underlying the negative correlation reported between low-density lipoprotein cholesterol concentration and the prognosis at the acute onset of MI and mortality. Clinical Trial Registration URL: http://www.clinicaltrials.gov. Unique identifier: NCT02405468.

Keywords: bacteria; blood metagenomics; blood microbiota; cholesterol; myocardial infarction.

Figures

Figure 1
Figure 1
Modifications of blood bacterial 16S rDNA concentration and diversity differentiate patients who had an MI. A, Mean concentrations (bar plot) and individual values (dot plot) of bacterial 16S rDNA assessed by qPCR in patients after MI or control patients. B, Mean concentrations (bar plots) and individual values (dot plots) of bacterial diversity (Shannon index) assessed by 16S metagenomic sequencing in patients after MI or control patients (*P<0.05; **P<0.01; ****P<0.0001). MI indicates myocardial infarction; qPCR, quantitative polymerase chain reaction.
Figure 2
Figure 2
Specific blood bacterial profiles assessed by 16S metagenomic sequencing characterize patients who had an MI. A, Mean relative proportions of bacterial phyla in blood of the overall study population. B, LEfSe analysis of the blood bacterial taxa correlated (red) or inversely correlated (green) with MI status. The cladograms represented here display all bacterial taxa sorter by phylogenic levels (from phyla at the center to genus at the outside rim). The bacterial taxa that are significantly different (P<0.05 with Mann–Whitney test) between the 2 groups being compared are displayed in green when more present in the control patients and in red when more present in the case patients. LEfSe, linear discriminant analysis effect size; MI, myocardial infarction.
Figure 3
Figure 3
Modification of proportions of blood bacterial taxa assessed by 16S metagenomic sequencing characterizes patients who had an MI. Mean (bar plots) and individual values (dot plots) of relative proportions of relevant blood bacterial taxa in patients after MI or control patients (*P<0.05; **P<0.01; ***P<0.001). MI indicates myocardial infarction.
Figure 4
Figure 4
Cholesterol‐degrading bacteria are decreased in patients with MI. A, Mean (bar plots) and individual values (dot plots) of relative proportions of blood bacterial taxa known to degrade cholesterol in patients after myocardial infarction or control patients. B, Modification of blood bacterial 16S rDNA concentration in patients who had an MI depends on the blood LDL cholesterol concentration. Mean (bar plots) and individual values (dot plots) concentrations of bacterial 16S rDNA assessed by qPCR in patients after myocardial infarction or control patients in subgroup of patients depending of LDL cholesterol concentration (*P<0.05; **P<0.01; ***P<0.001; ****P<0.0001; ns: not significant). LDL indicates low‐density lipoprotein; MI, myocardial infarction; qPCR, quantitative polymerase chain reaction.

References

    1. Wiedermann CJ, Kiechl S, Dunzendorfer S, Schratzberger P, Egger G, Oberhollenzer F, Willeit J. Association of endotoxemia with carotid atherosclerosis and cardiovascular disease: prospective results from the Bruneck Study. J Am Coll Cardiol. 1999;34:1975–1981.
    1. Wang Z, Klipfell E, Bennett BJ, Koeth R, Levison BS, Dugar B, Feldstein AE, Britt EB, Fu X, Chung YM, Wu Y, Schauer P, Smith JD, Allayee H, Tang WH, DiDonato JA, Lusis AJ, Hazen SL. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature. 2011;472:57–65.
    1. Tang WHW, Wang Z, Levison BS, Koeth RA, Britt EB, Fu X, Wu Y, Hazen SL. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. N Engl J Med. 2013;368:1575–1584.
    1. Rogler G, Rosano G. The heart and the gut. Eur Heart J. 2014;35:426–430.
    1. Ahmadmehrabi S, Tang WHW. Gut microbiome and its role in cardiovascular diseases. Curr Opin Cardiol. 2017;32:761–766.
    1. Chen K, Zheng X, Feng M, Li D, Zhang H. Gut microbiota‐dependent metabolite trimethylamine N‐oxide contributes to cardiac dysfunction in Western diet‐induced obese mice. Front Physiol. 2017;8:139.
    1. Karlsson FH, Fåk F, Nookaew I, Tremaroli V, Fagerberg B, Petranovic D, Bäckhed F, Nielsen J. Symptomatic atherosclerosis is associated with an altered gut metagenome. Nat Commun. 2012;3:1245.
    1. Mitra S, Drautz‐Moses DI, Alhede M, Maw MT, Liu Y, Purbojati RW, Yap ZH, Kushwaha KK, Gheorghe AG, Bjarnsholt T, Hansen GM, Sillesen HH, Hougen HP, Hansen PR, Yang L, Tolker‐Nielsen T, Schuster SC, Givskov M. In silico analyses of metagenomes from human atherosclerotic plaque samples. Microbiome. 2015;3:38.
    1. Lindskog Jonsson A, Hållenius FF, Akrami R, Johansson E, Wester P, Arnerlöv C, Bäckhed F, Bergström G. Bacterial profile in human atherosclerotic plaques. Atherosclerosis. 2017;263:177–183.
    1. Lluch J, Servant F, Païssé S, Valle C, Valière S, Kuchly C, Vilchez G, Donnadieu C, Courtney M, Burcelin R, Amar J, Bouchez O, Lelouvier B. The characterization of novel tissue microbiota using an optimized 16S metagenomic sequencing pipeline. PLoS One. 2015;10:e0142334.
    1. Païssé S, Valle C, Servant F, Courtney M, Burcelin R, Amar J, Lelouvier B. Comprehensive description of blood microbiome from healthy donors assessed by 16S targeted metagenomic sequencing. Transfusion. 2016;56:1138–1147.
    1. Lelouvier B, Servant F, Païssé S, Brunet A‐C, Benyahya S, Serino M, Valle C, Ortiz MR, Puig J, Courtney M, Federici M, Fernández‐Real J‐M, Burcelin R, Amar J. Changes in blood microbiota profiles associated with liver fibrosis in obese patients: a pilot analysis. Hepatology. 2016;64:2015–2027.
    1. Amar J, Lange C, Payros G, Garret C, Chabo C, Lantieri O, Courtney M, Marre M, Charles MA, Balkau B, Burcelin R. Blood microbiota dysbiosis is associated with the onset of cardiovascular events in a large general population: the D.E.S.I.R. study. PLoS One. 2013;8:e54461.
    1. Krack A, Sharma R, Figulla HR, Anker SD. The importance of the gastrointestinal system in the pathogenesis of heart failure. Eur Heart J. 2005;26:2368–2374.
    1. Zabell A, Tang WHW. Targeting the microbiome in heart failure. Curr Treat Options Cardiovasc Med. 2017;19:27.
    1. Sandek A, Bauditz J, Swidsinski A, Buhner S, Weber‐Eibel J, von Haehling S, Schroedl W, Karhausen T, Doehner W, Rauchhaus M, Poole‐Wilson P, Volk H‐D, Lochs H, Anker SD. Altered intestinal function in patients with chronic heart failure. J Am Coll Cardiol. 2007;50:1561–1569.
    1. Sandek A, Swidsinski A, Schroedl W, Watson A, Valentova M, Herrmann R, Scherbakov N, Cramer L, Rauchhaus M, Grosse‐Herrenthey A, Krueger M, von Haehling S, Doehner W, Anker SD, Bauditz J. Intestinal blood flow in patients with chronic heart failure: a link with bacterial growth, gastrointestinal symptoms, and cachexia. J Am Coll Cardiol. 2014;64:1092–1102.
    1. Herbert KE, Erridge C. Regulation of low‐density lipoprotein cholesterol by intestinal inflammation and the acute phase response. Cardiovasc Res. 2018;114:226–232.
    1. Cheng KH, Chu CS, Lin TH, Lee KT, Sheu SH, Lai WT. Lipid paradox in acute myocardial infarction‐the association with 30‐day in‐hospital mortality. Crit Care Med. 2015;43:1255–1264.
    1. Reddy VS, Bui QT, Jacobs JR, Begelman SM, Miller DP, French WJ. Relationship between serum low‐density lipoprotein cholesterol and in‐hospital mortality following acute myocardial infarction (the lipid paradox). Am J Cardiol. 2015;115:557–562.
    1. Segata N, Izard J, Waldron L, Gevers D, Miropolsky L, Garrett WS, Huttenhower C. Metagenomic biomarker discovery and explanation. Genome Biol. 2011;12:R60.
    1. Kreit J, Sampson NS. Cholesterol oxidase: physiological functions. FEBS J. 2009;276:6844–6856.
    1. García JL, Uhía I, Galán B. Catabolism and biotechnological applications of cholesterol degrading bacteria. Microb Biotechnol. 2012;5:679–699.
    1. Balmer ML, Slack E, de Gottardi A, Lawson MA, Hapfelmeier S, Miele L, Grieco A, Van Vlierberghe H, Fahrner R, Patuto N, Bernsmeier C, Ronchi F, Wyss M, Stroka D, Dickgreber N, Heim MH, McCoy KD, Macpherson AJ. The liver may act as a firewall mediating mutualism between the host and its gut commensal microbiota. Sci Transl Med. 2014;6:237ra66.
    1. Husic M, Nørager B, Egstrup K, Lang RM, Møller JE. Diastolic wall motion abnormality after myocardial infarction: relation to neurohormonal activation and prognostic implications. Am Heart J. 2005;150:767–774.
    1. Wen SW, Wong CHY. An unexplored brain‐gut microbiota axis in stroke. Gut Microbes. 2017;8:601–606.
    1. Stanley D, Mason LJ, MacKin KE, Srikhanta YN, Lyras D, Prakash MD, Nurgali K, Venegas A, Hill MD, Moore RJ, Wong CHY. Translocation and dissemination of commensal bacteria in post‐stroke infection. Nat Med. 2016;22:1277–1284.
    1. Lelouvier B, Servant F, Delobel P, Courtney M, Elbaz M, Amar J. Identification by highly sensitive 16S metagenomic sequencing of an unusual case of polymicrobial bacteremia. J Infect. 2017;75:278–280.
    1. Rasmussen BA, Breen DM, Lam TKT. Lipid sensing in the gut, brain and liver. Trends Endocrinol Metab. 2012;23:49–55.
    1. Qi C‐J, Zhang Q, Yu M, Xu J‐P, Zheng J, Wang T, Xiao X‐H. Imbalance of fecal microbiota at newly diagnosed type 1 diabetes in Chinese children. Chin Med J (Engl). 2016;129:1298–1304.
    1. Kang SS, Jeraldo PR, Kurti A, Miller ME, Cook MD, Whitlock K, Goldenfeld N, Woods JA, White BA, Chia N, Fryer JD. Diet and exercise orthogonally alter the gut microbiome and reveal independent associations with anxiety and cognition. Mol Neurodegener. 2014;9:36.

Source: PubMed

3
購読する